NEW YORK, June 07, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces the filing of class action lawsuits against Amber Road, Inc. (NYSE: AMBR) and Aratana.
LEAWOOD, Kan., June 11, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved an additional vial size (10 mL) for NOCITA® (bupivacaine liposome injectable suspension). NOCITA is currently available in a 20 mL vial size and Aratana continues to anticipate commercial availability of the NOCITA 10 mL vial by fall 2019.
WILMINGTON, Del., June 24, 2019 -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
ELAN earnings call for the period ending June 30, 2019.
NEW YORK, June 06, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces that class action lawsuits were filed against Aratana Therapeutics, Inc. (NASDAQ:.
Stockholders Elect All Class III Directors and Approve Proposals LEAWOOD, Kan. , June 7, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development ...
NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces the filing of shareholder class action lawsuits against Cray Inc. (NASDAQ: CRAY) and Aratana Therapeutics, ...
LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. The Company reported approximately 72% (35,269,237) of the Company's common stock outstanding as of the July 14, 2019 record date adopted the merger agreement.
TÜBINGEN, Germany and BOSTON, June 24, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that Timothy Wright, M.D. and Craig Tooman were elected as independent directors to CureVac’s Supervisory Board at the Company’s Annual General Meeting. These new members will support CureVac’s mission to use mRNA to revolutionize human health with their vast drug development and operational expertise. Their appointments increase CureVac’s Supervisory Board from six to eight directors.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]